Home \ PRAZIKVANTEL

PRAZIKVANTEL

prazikvantel.jpg
1. GENERAL INFORMATION
1.1 Prazikvantel is an anthelminthic formulation containing 50 mg of praziquantel per tablet as an active ingredient and other auxiliary components. Polymer-coated granules with taste attractants contain 25 mg of praziquantel.

1.2 Prazikvantel is pre-packaged by 5, 10, 50, 100, 110 and 500 tablets or granules in blister or plastic packaging, placed into cardboard box.

1.3 Product should be stored with caution (List B) in the original packaging in dark place and protected from moisture ingress at temperatures -8 °C to 25 °C. Shelf life is 3 years under specified storage conditions.

2. PHARMACOLOGICAL PROPERTIES
2.1 Praziquantel is a broad-spectrum anthelminthic used for treatment of echinococcosis, difilobotrioze, dipilidoze, gidatigeroze, multitseptoze and orientobilhartsioze in animals.

2.2 Mechanism of drug’s action is inhibition of fumarate treduktase, inappropriate cell membrane permeability and neuromuscular innervations resulting in paralysis and worms death.

2.3 Preparation has a low toxicity to warm-blooded animals (LD50 for mice by oral administration is 2650 mg / kg). It does not have any local irritation, embryotoxic, teratogenic and sensitizing effects in recommended doses.

 

3. DRUG USAGE PROCEDURE
3.1 Prazikvantel is used only once during echinococcus, difilobotriose, dipilidose, gidatigerose, multitseptose orientobilhartsiose for dehelminthization of animals.

3.2 Granules or tablets of praziquantel preparation are administered once individually orally by animals inside without prior starvation diet. Preparation is put directly into animal’s mouth (base of tongue) or feed wrapped into meat, sausage or in a powdered form mixed with food.            

3.3 Dogs and cats are de-wormed with prevention affect every quarter by using afore mentioned dose.

 

4. INDIVIDUAL PREVENTION MEASURES
4.1 When working with preparation one should observe proper personal hygiene and safety requirements prescribed for operations with veterinary drugs.

 

5. CLAIMS PROCEDURE
5.1 In case of inconsistency of the drug with requirements of this Instruction, its use should be discontinued and reported to the Uzbek state scientific and veterinary drugs control laboratory at: 700178, Tashkent, No.1a, A.Yunusov Street. Tel. / Fax: 228-76-14, 229-30 - 47. E-mail: uzgnkl@rambler.ru. Simultaneously unpacked drug package should be sent to the laboratory address with the drug in quantity previously agreed with laboratory including detailed description of the nature of complications.